US20220339213A1 - Probiotic compositions and methods of use thereof - Google Patents
Probiotic compositions and methods of use thereof Download PDFInfo
- Publication number
- US20220339213A1 US20220339213A1 US17/730,850 US202217730850A US2022339213A1 US 20220339213 A1 US20220339213 A1 US 20220339213A1 US 202217730850 A US202217730850 A US 202217730850A US 2022339213 A1 US2022339213 A1 US 2022339213A1
- Authority
- US
- United States
- Prior art keywords
- subject
- propionibacterium
- bacteria
- composition
- strain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 104
- 238000000034 method Methods 0.000 title claims abstract description 65
- 239000006041 probiotic Substances 0.000 title claims abstract description 54
- 235000018291 probiotics Nutrition 0.000 title claims abstract description 54
- 230000000529 probiotic effect Effects 0.000 title claims abstract description 52
- 241000894006 Bacteria Species 0.000 claims abstract description 75
- 241000186428 Propionibacterium freudenreichii Species 0.000 claims abstract description 23
- 210000002966 serum Anatomy 0.000 claims abstract description 16
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims abstract description 10
- 229930003779 Vitamin B12 Natural products 0.000 claims abstract description 8
- 230000008901 benefit Effects 0.000 claims abstract description 8
- 235000019163 vitamin B12 Nutrition 0.000 claims abstract description 8
- 239000011715 vitamin B12 Substances 0.000 claims abstract description 8
- 230000033228 biological regulation Effects 0.000 claims abstract description 6
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 claims abstract description 5
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 claims abstract description 5
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims abstract description 5
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims abstract description 5
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims abstract description 5
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims abstract description 5
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims abstract description 5
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims abstract description 5
- 229930003471 Vitamin B2 Natural products 0.000 claims abstract description 5
- 229930003571 Vitamin B5 Natural products 0.000 claims abstract description 5
- LXNHXLLTXMVWPM-UHFFFAOYSA-N Vitamin B6 Natural products CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims abstract description 5
- 229930003761 Vitamin B9 Natural products 0.000 claims abstract description 5
- 230000003416 augmentation Effects 0.000 claims abstract description 5
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims abstract description 5
- 210000000987 immune system Anatomy 0.000 claims abstract description 5
- 239000002207 metabolite Substances 0.000 claims abstract description 5
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims abstract description 5
- 230000000770 proinflammatory effect Effects 0.000 claims abstract description 5
- 235000019260 propionic acid Nutrition 0.000 claims abstract description 5
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 claims abstract description 5
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 claims abstract description 5
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 claims abstract description 5
- 230000009467 reduction Effects 0.000 claims abstract description 5
- 229960002477 riboflavin Drugs 0.000 claims abstract description 5
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims abstract description 5
- 235000019164 vitamin B2 Nutrition 0.000 claims abstract description 5
- 239000011716 vitamin B2 Substances 0.000 claims abstract description 5
- 239000011675 vitamin B5 Substances 0.000 claims abstract description 5
- 235000009492 vitamin B5 Nutrition 0.000 claims abstract description 5
- 235000019158 vitamin B6 Nutrition 0.000 claims abstract description 5
- 239000011726 vitamin B6 Substances 0.000 claims abstract description 5
- 235000019159 vitamin B9 Nutrition 0.000 claims abstract description 5
- 239000011727 vitamin B9 Substances 0.000 claims abstract description 5
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 claims abstract 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 16
- 235000013406 prebiotics Nutrition 0.000 claims description 13
- 241000186429 Propionibacterium Species 0.000 claims description 11
- 102000011990 Sirtuin Human genes 0.000 claims description 10
- 108050002485 Sirtuin Proteins 0.000 claims description 10
- 239000003623 enhancer Substances 0.000 claims description 10
- 235000019722 synbiotics Nutrition 0.000 claims description 10
- 241000186425 Acidipropionibacterium jensenii Species 0.000 claims description 8
- 241000186335 Acidipropionibacterium thoenii Species 0.000 claims description 8
- 241001464974 Cutibacterium avidum Species 0.000 claims description 8
- 241001464975 Cutibacterium granulosum Species 0.000 claims description 8
- 241001464976 Propionimicrobium lymphophilum Species 0.000 claims description 8
- 239000004310 lactic acid Substances 0.000 claims description 8
- 235000014655 lactic acid Nutrition 0.000 claims description 8
- 229940055009 propionibacterium avidum Drugs 0.000 claims description 8
- 241000193830 Bacillus <bacterium> Species 0.000 claims description 7
- 241000186000 Bifidobacterium Species 0.000 claims description 7
- 241000186427 Cutibacterium acnes Species 0.000 claims description 7
- 241000186660 Lactobacillus Species 0.000 claims description 7
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 7
- 210000004027 cell Anatomy 0.000 claims description 7
- 229940055019 propionibacterium acne Drugs 0.000 claims description 7
- 229960002181 saccharomyces boulardii Drugs 0.000 claims description 7
- BAWFJGJZGIEFAR-NNYOXOHSSA-O NAD(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-O 0.000 claims description 4
- 206010034133 Pathogen resistance Diseases 0.000 claims description 4
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 4
- 230000004721 adaptive immunity Effects 0.000 claims description 4
- 230000032683 aging Effects 0.000 claims description 4
- 230000001332 colony forming effect Effects 0.000 claims description 4
- 230000036039 immunity Effects 0.000 claims description 4
- 230000007423 decrease Effects 0.000 claims description 3
- 208000020154 Acnes Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 21
- 201000010099 disease Diseases 0.000 description 13
- 235000013305 food Nutrition 0.000 description 10
- 235000015872 dietary supplement Nutrition 0.000 description 9
- 208000035475 disorder Diseases 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 206010061218 Inflammation Diseases 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 230000004054 inflammatory process Effects 0.000 description 7
- 239000004615 ingredient Substances 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 235000013351 cheese Nutrition 0.000 description 6
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 6
- 238000011049 filling Methods 0.000 description 6
- 230000001575 pathological effect Effects 0.000 description 6
- -1 acidulants (e.g. Substances 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 235000013361 beverage Nutrition 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 235000016709 nutrition Nutrition 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000000855 fermentation Methods 0.000 description 3
- 230000004151 fermentation Effects 0.000 description 3
- 235000012041 food component Nutrition 0.000 description 3
- 239000005417 food ingredient Substances 0.000 description 3
- 235000013376 functional food Nutrition 0.000 description 3
- 208000027866 inflammatory disease Diseases 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 230000033616 DNA repair Effects 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 2
- 229920002774 Maltodextrin Polymers 0.000 description 2
- 239000005913 Maltodextrin Substances 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000006172 buffering agent Substances 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 235000013353 coffee beverage Nutrition 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 235000013373 food additive Nutrition 0.000 description 2
- 239000002778 food additive Substances 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000009610 hypersensitivity Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 210000002429 large intestine Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000001630 malic acid Substances 0.000 description 2
- 235000011090 malic acid Nutrition 0.000 description 2
- 229940035034 maltodextrin Drugs 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 210000003289 regulatory T cell Anatomy 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 201000000306 sarcoidosis Diseases 0.000 description 2
- 230000009469 supplementation Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 235000013618 yogurt Nutrition 0.000 description 2
- GMVPRGQOIOIIMI-UHFFFAOYSA-N (8R,11R,12R,13E,15S)-11,15-Dihydroxy-9-oxo-13-prostenoic acid Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CCCCCCC(O)=O GMVPRGQOIOIIMI-UHFFFAOYSA-N 0.000 description 1
- BJRMBXPQAMDCMG-CMJQBAFXSA-N 20-hydroxy-leukotriene E4 Chemical compound OC(=O)CCC[C@H](O)[C@H](SC[C@H](N)C(O)=O)\C=C\C=C\C=C/C\C=C/CCCCCO BJRMBXPQAMDCMG-CMJQBAFXSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108010074051 C-Reactive Protein Proteins 0.000 description 1
- 102100032752 C-reactive protein Human genes 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 208000031879 Chédiak-Higashi syndrome Diseases 0.000 description 1
- 208000015943 Coeliac disease Diseases 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 102100025621 Cytochrome b-245 heavy chain Human genes 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- 208000005615 Interstitial Cystitis Diseases 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- 206010024229 Leprosy Diseases 0.000 description 1
- 240000002129 Malva sylvestris Species 0.000 description 1
- 235000006770 Malva sylvestris Nutrition 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 201000002481 Myositis Diseases 0.000 description 1
- 206010051606 Necrotising colitis Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 208000029082 Pelvic Inflammatory Disease Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 201000009594 Systemic Scleroderma Diseases 0.000 description 1
- 206010042953 Systemic sclerosis Diseases 0.000 description 1
- 241000255588 Tephritidae Species 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000009470 Theobroma cacao Nutrition 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 208000010011 Vitamin A Deficiency Diseases 0.000 description 1
- 108010046377 Whey Proteins Proteins 0.000 description 1
- 102000007544 Whey Proteins Human genes 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 229960000711 alprostadil Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001722 carbon compounds Chemical class 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- PBAYDYUZOSNJGU-UHFFFAOYSA-N chelidonic acid Natural products OC(=O)C1=CC(=O)C=C(C(O)=O)O1 PBAYDYUZOSNJGU-UHFFFAOYSA-N 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000016532 chronic granulomatous disease Diseases 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 229910052681 coesite Inorganic materials 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 229910052906 cristobalite Inorganic materials 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 201000001981 dermatomyositis Diseases 0.000 description 1
- 235000011850 desserts Nutrition 0.000 description 1
- 208000033679 diabetic kidney disease Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 235000018823 dietary intake Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 235000012489 doughnuts Nutrition 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 235000020774 essential nutrients Nutrition 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 230000004136 fatty acid synthesis Effects 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000013350 formula milk Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000000054 fungal extract Substances 0.000 description 1
- 201000010175 gallbladder cancer Diseases 0.000 description 1
- 201000007487 gallbladder carcinoma Diseases 0.000 description 1
- 239000007897 gelcap Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 208000010758 granulomatous inflammation Diseases 0.000 description 1
- 244000005709 gut microbiome Species 0.000 description 1
- 230000007407 health benefit Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 235000015092 herbal tea Nutrition 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 201000008319 inclusion body myositis Diseases 0.000 description 1
- 229940029329 intrinsic factor Drugs 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 208000004995 necrotizing enterocolitis Diseases 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 235000021140 nondigestible carbohydrates Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Polymers 0.000 description 1
- 210000004789 organ system Anatomy 0.000 description 1
- 238000006053 organic reaction Methods 0.000 description 1
- 235000016046 other dairy product Nutrition 0.000 description 1
- 238000002638 palliative care Methods 0.000 description 1
- 201000006195 perinatal necrotizing enterocolitis Diseases 0.000 description 1
- 201000001245 periodontitis Diseases 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 208000005987 polymyositis Diseases 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- GMVPRGQOIOIIMI-DWKJAMRDSA-N prostaglandin E1 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O GMVPRGQOIOIIMI-DWKJAMRDSA-N 0.000 description 1
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 1
- 201000007094 prostatitis Diseases 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 235000013322 soy milk Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 229910052682 stishovite Inorganic materials 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 208000006379 syphilis Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 229910052905 tridymite Inorganic materials 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 235000020806 vegan diet Nutrition 0.000 description 1
- 235000003563 vegetarian diet Nutrition 0.000 description 1
- 208000002670 vitamin B12 deficiency Diseases 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 235000021119 whey protein Nutrition 0.000 description 1
- 235000008924 yoghurt drink Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
- A61K36/064—Saccharomycetales, e.g. baker's yeast
Definitions
- Vitamin B12 is important for the normal functioning of the brain and nervous system and for the formation of blood. It is involved in the metabolism of every cell of the body, especially affecting the DNA synthesis and regulation but also fatty acid synthesis and energy production. Its effects are still not completely known.
- Vitamin B12 deficiencies can result in significant damage to multiple organ systems and supplementation is often required, especially among individuals that have vegetarian or vegan diets, or that are pregnant. There is a need in the art for improved compositions and methods for supplementing vitamin B12.
- a composition comprising: at least one strain of bacteria wherein the at least one strain of bacteria comprises Propionibacterium freudenreichii UF (UF1).
- the UF1 is probiotic.
- the composition administered delivers a dose of UF1 to the subject from about 5 ⁇ 10 8 to about 1 ⁇ 10 11 colony forming units (CFU).
- the dose of UF1 is from about 1 ⁇ 10 9 to about 2 ⁇ 10 10 CFU.
- the dose of UF1 is from about 5 ⁇ 10 9 to about 1 ⁇ 10 10 CFU.
- the composition administered delivers a dose of UF1 to the subject from about 5 ⁇ 10 8 to about 1 ⁇ 10 11 Active Fluorescent Units (AFU).
- AFU Active Fluorescent Units
- the dose of UF1 is from about 1 ⁇ 10 9 to about 2 ⁇ 10 10 AFU.
- the dose of UF1 is from about 5 ⁇ 10 9 to about 1 ⁇ 10 10 AFU.
- the UF1 is a mixture of probiotic and paraprobiotic. In exemplary implementations, the UF1 is parabiotic. In further embodiments, the UF1 is a probiotic, parabiotic, prebiotic, synbiotic, or mixture of the foregoing.
- the administration of the composition increases the subject's serum B12 levels by at least about 10% relative to the subject's serum B12 level prior to administration of the composition.
- the administration of the composition confers at least on benefit on the subject selected from; an increase in serum levels of at least one of vitamin B2, B5, B6, B9, and/or B12; an increase in at least one of tryptophan, tyrosine, phenylalanine; increased propionic acid, immune system modulation and/or augmentation, regulation of TH17 cells; and/or reduction in pro-inflammatory metabolites.
- administration of the composition to the subject increases the level of NAD+ and or NMN levels in the subject.
- the at least one strain of bacteria comprises at least a second strain of bacteria chosen from: Propionibacterium acnes; Propionibacterium avidum; Propionibacterium granulosum; Propionibacterium lymphophilum; Propionibacterium acidiproprionic; Propionibacterium jensenii Propionibacterium thoenii ; lactic acid bacteria including lactobacilli (ssp. acidophilus, fermentum, plantarum, rhamnosus, casei, reuteri, gasseri ) and streptococci (e.g. salivarius, thermophilus ), spore forming bacteria including Bacillus (e.g. coagulans, subtilis ), bifidobacteria, yeast-derived bacteria including Saccharomyces boulardii , and/or mixtures of the foregoing.
- lactobacilli ssp. acidophilus, fermentum, plantarum, rhamnosus, casei, reuteri, gasseri
- the subject is an infant.
- administration of the composition to the infant accelerates T-cell immunity, decreases neonatal adaptive immunity period, and/or increases pathogen resistance.
- the infant was born preterm.
- a method of slowing aging in a subject comprising administering to the subject one or more sirtuin enhancer to the subject, wherein the one or more sirtuin enhancer comprises at least one strain of bacteria wherein the at least one strain of bacteria comprises Propionibacterium freudenreichii UF (UF1).
- a probiotic composition comprising Propionibacterium freudenreichii UF (UF1) and at least a second strain of probiotic bacteria wherein the second strain of probiotic bacteria is selected from: Propionibacterium acnes; Propionibacterium avidum; Propionibacterium granulosum; Propionibacterium lymphophilum; Propionibacterium acidiproprionic; Propionibacterium jensenii Propionibacterium thoenii ; lactic acid bacteria including lactobacilli (ssp. acidophilus, fermentum, plantarum, rhamnosus, casei, reuteri, gasseri ) and streptococci (e.g.
- spore forming bacteria including Bacillus (e.g. coagulans, subtilis ), bifidobacteria, yeast-derived bacteria including Saccharomyces boulardii , prebiotics, and synbiotics and/or mixtures of the foregoing.
- Ranges can be expressed herein as from “about” one particular value, and/or to “about” another particular value. When such a range is expressed, a further aspect includes from the one particular value and/or to the other particular value. Similarly, when values are expressed as approximations, by use of the antecedent “about,” it will be understood that the particular value forms a further aspect. It will be further understood that the endpoints of each of the ranges are significant both in relation to the other endpoint, and independently of the other endpoint. It is also understood that there are a number of values disclosed herein, and that each value is also herein disclosed as “about” that particular value in addition to the value itself. For example, if the value “10” is disclosed, then “about 10” is also disclosed. It is also understood that each unit between two particular units are also disclosed. For example, if 10 and 15 are disclosed, then 11, 12, 13, and 14 are also disclosed.
- Certain materials, compounds, compositions, and components disclosed herein can be obtained commercially or readily synthesized using techniques generally known to those of skill in the art.
- the starting materials and reagents used in preparing the disclosed compounds and compositions are either available from commercial suppliers such as Aldrich Chemical Co., (Milwaukee, Wis.), Acros Organics (Morris Plains, N.J.), Fisher Scientific (Pittsburgh, Pa.), or Sigma (St.
- probiotic bacteria or “probiotics” as used herein, refers to microorganisms which when administered for nutritional supplementation in adequate amounts confer a health benefit to the subject.
- Heath benefit can be measured by any method known in the art, for example, as indicated by biochemical markers including for example, blood sugar levels, lipid chemistry, liver function, full blood count, thyroid function, markers of inflammation (ESR and C-reactive protein), and stool classifications.
- biochemical markers including for example, blood sugar levels, lipid chemistry, liver function, full blood count, thyroid function, markers of inflammation (ESR and C-reactive protein), and stool classifications.
- a probiotic such as the composition disclosed herein, is optionally combined with at least one suitable prebiotic compound.
- a prebiotic compound is usually a non-digestible carbohydrate such as an oligo- or polysaccharide, or a sugar alcohol, which is not degraded or absorbed in the upper digestive tract.
- Known prebiotics include commercial products such as inulin and transgalacto-oligosaccharides.
- paraprobiotic bacteria or “paraprobiotic” means those products comprising killed or inactivated microbes which may positively affect subject health.
- the term “probiotic composition” can refer to a composition containing at least one species, genus, family, strain, order, or class of probiotic bacteria (e.g., a single isolate or a combination of desired bacteria), and can also include any additional carriers, excipients, and/or therapeutic agents that can be administered to a mammal.
- the probiotic composition comprises a buffering agent to allow the probiotic bacteria to survive in the acidic environment of the stomach, that is, the probiotic bacteria resist low pH and are able to survive passage through the stomach to colonize and grow in the intestinal milieu.
- Buffering agents can include, for example, sodium bicarbonate, milk, yoghurt, infant formula, and other dairy products.
- the probiotic composition is formulated as a food additive.
- the probiotic composition includes other materials known in the art for inclusion in food additives, such as water or other aqueous solutions, starch, binders, thickeners, colorants, flavorants, odorants, acidulants (e.g., lactic acid or malic acid, among others), vitamins, or minerals, among others.
- treatment refers to the medical management of a patient with the intent to cure, ameliorate, stabilize, or prevent a disease, pathological condition, or disorder.
- This term includes active treatment, that is, treatment directed specifically toward the improvement of a disease, pathological condition, or disorder, and also includes causal treatment, that is, treatment directed toward removal of the cause of the associated disease, pathological condition, or disorder.
- this term includes palliative treatment, that is, treatment designed for the relief of symptoms rather than the curing of the disease, pathological condition, or disorder; preventative treatment, that is, treatment directed to minimizing or partially or completely inhibiting the development of the associated disease, pathological condition, or disorder; and supportive treatment, that is, treatment employed to supplement another specific therapy directed toward the improvement of the associated disease, pathological condition, or disorder.
- the term covers any treatment of a subject, including a mammal (e.g., a human), and includes: (i) preventing the disease from occurring in a subject that can be predisposed to the disease but has not yet been diagnosed as having it; (ii) inhibiting the disease, i.e., arresting its development; or (iii) relieving the disease, i.e., causing regression of the disease.
- the subject is a mammal such as a primate, and, in a further aspect, the subject is a human.
- subject also includes domesticated animals (e.g., cats, dogs, etc.), livestock (e.g., cattle, horses, pigs, sheep, goats, etc.), and laboratory animals (e.g., mouse, rabbit, rat, guinea pig, fruit fly, etc.).
- domesticated animals e.g., cats, dogs, etc.
- livestock e.g., cattle, horses, pigs, sheep, goats, etc.
- laboratory animals e.g., mouse, rabbit, rat, guinea pig, fruit fly, etc.
- the terms “effective amount” and “amount effective” refer to an amount that is sufficient to achieve the desired result or to have an effect on an undesired condition.
- a “therapeutically effective amount” refers to an amount that is sufficient to achieve the desired therapeutic result or to have an effect on undesired symptoms, but is generally insufficient to cause adverse side effects.
- the specific therapeutically effective dose level for any particular patient will depend upon a variety of factors including the disorder being treated and the severity of the disorder; the specific composition employed; the age, body weight, general health, sex and diet of the patient; the time of administration; the route of administration; the rate of excretion of the specific compound employed; the duration of the treatment; drugs used in combination or coincidental with the specific compound employed and like factors well known in the medical arts. For example, it is well within the skill of the art to start doses of a compound at levels lower than those required to achieve the desired therapeutic effect and to gradually increase the dosage until the desired effect is achieved. If desired, the effective daily dose can be divided into multiple doses for purposes of administration.
- compositions can contain such amounts or submultiples thereof to make up the daily dose.
- the dosage can be adjusted by the individual physician in the event of any contraindications. Dosage can vary, and can be administered in one or more dose administrations daily, for one or several days. Guidance can be found in the literature for appropriate dosages for given classes of pharmaceutical products.
- a preparation can be administered in a “prophylactically effective amount”; that is, an amount effective for prevention of a disease or condition.
- the term “substantially” refers to the complete or nearly complete extent or degree of an action, characteristic, property, state, structure, item, or result.
- an object that is “substantially” enclosed would mean that the object is either completely enclosed or nearly completely enclosed.
- the exact allowable degree of deviation from absolute completeness may in some cases depend on the specific context. However, generally speaking the nearness of completion will be so as to have the same overall result as if absolute and total completion were obtained.
- the use of “substantially” is equally applicable when used in a negative connotation to refer to the complete or near complete lack of an action, characteristic, property, state, structure, item, or result.
- compositions that is “substantially free of” particles would either completely lack particles, or so nearly completely lack particles that the effect would be the same as if it completely lacked particles.
- a composition that is “substantially free of an ingredient or element may still actually contain such item as long as there is no measurable effect thereof.
- Propionibacterium freudenreichii is a gram-positive, non-motile bacterium that plays an important role in the creation of Emmental cheese, and to some extent, Jarlsberg cheese, Leerdammer and Maasdam cheese. Its concentration in Swiss-type cheeses is higher than in any other cheese.
- Propionibacterium strain, P. UF1 has been isolated from the gut microbiota of preterm infants.
- P. UF1 is also referred to herein as Propionibacterium freudenheimii UF1 or UF1.
- a method for increasing vitamin B12 levels in a subject comprising administering to the subject a composition comprising: at least one strain of bacteria wherein the at least one strain of bacteria comprises Propionibacterium freudenreichii UF (UF1).
- the composition administered delivers a dose of UF1 to the subject from about 5 ⁇ 10 8 to about 1 ⁇ 10 11 colony forming units (CFU).
- the dose of UF1 provided is from about 1 ⁇ 10 9 to about 2 ⁇ 10 10 CFU.
- the dose of UF1 is from about 5 ⁇ 10 9 to about 1 ⁇ 10 10 CFU.
- the amount of UF1 present in a dose is determined by flow cytometry to determine the number of live cells, as measured by Active Fluorescent Units (AFU).
- the composition administered delivers a dose of UF1 to the subject from about 5 ⁇ 10 8 to about 1 ⁇ 10 11 AFU.
- the dose of UF1 provided is from about 1 ⁇ 10 9 to about 2 ⁇ 10 10 AFU.
- the dose of UF1 is from about 5 ⁇ 10 9 to about 1 ⁇ 10 10 AFU.
- the at least one strain of bacteria is a probiotic. In further embodiments, the at least once strain of bacteria is a paraprobiotic.
- the composition further comprises a prebiotic and/or a synbiotic.
- the at least on strain of bacteria is a mixture of a probiotic and paraprobiotic, prebiotic, and/or synbiotic.
- administration of the disclosed composition increases the subject's serum B12 levels. This is surprising given that it has been viewed as unlikely that administration of a probiotic vB12 producing bacteria would be able to affect serum vB12 levels. This is because while Propionibacterium UF1 is known to produce vB12 under industrial or lab conditions, it is unlikely that a substrate required by make B12 by UF1 occurs in the human gut. Furthermore, B12 is absorbed in the small intestine. B12 must be combined with intrinsic factor, a protein that is produced in the stomach to be absorbed. Probiotics usually reside (they are transient and do not colonize) in the large intestine, meaning the probiotic would be making B12 in the large intestine which is past its site of absorption.
- administration of the disclosed composition to a subject results in an increases in serum B12 level in the subject by at least 5%, at least 10%, at least 25%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or more, compared to the subject's B12 serum level prior to administration of the composition.
- administration of the disclosed composition confers at least or many benefits on the subject.
- the subject has reduced inflammation.
- the subject has an increase in serum levels of at least one of vitamin B2, B5, B6, B9, and/or B12.
- the subject has an increase in levels of at least one amino acid. These include, but are not limited to tryptophan, tyrosine, and/or phenylalanine.
- the subject has increased levels of propionic acid, which in turn can has a positive impact on the intestinal regulatory cells, including induced T regulatory cells (Treg cells).
- the subject has benefits to immune system modulation and/or augmentation. In yet further embodiments, the subject has beneficial effects on the regulation of TH17 cells. In still further embodiments, the subject has a reduction in pro-inflammatory metabolites.
- the probiotic composition also includes one or more additional strain of bacteria.
- this may include one or more of: Propionibacterium acnes; Propionibacterium avidum; Propionibacterium granulosum; Propionibacterium lymphophilum; Propionibacterium acidiproprionic; Propionibacterium jensenii Propionibacterium thoenii ; lactic acid bacteria including lactobacilli (ssp. acidophilus, fermentum, plantarum, rhamnosus, casei, reuteri, gasseri ) and streptococci (e.g. salivarius, thermophilus ), spore forming bacteria including Bacillus (e.g.
- second strain of bacteria is a probiotic or a parabiotic or a mixture of the foregoing.
- the composition further comprises a prebiotic, and/or synbiotic or mixtures of the foregoing.
- the subject is an infant.
- the infant experiences one or more of the following benefits from administration of the probiotic composition: accelerated T-cell immunity, decreased neonatal adaptive immunity period, and/or increased pathogen resistance.
- the infant was born preterm.
- an inflammatory disease or condition may include, but is not limited to: acne vulgaris, asthma, COPD, autoimmune diseases, celiac disease, chronic (plaque) prostatitis, glomerulonephritis, hypersensitivities, inflammatory bowel diseases (IBD, Crohn's disease, ulcerative colitis), pelvic inflammatory disease, reperfusion injury, rheumatoid arthritis, sarcoidosis, transplant rejection, vasculitis, interstitial cystitis, atherosclerosis, allergies (type 1, 2, and 3 hypersensitivity, hay fever), inflammatory myopathies, as systemic sclerosis, and include dermatomyositis, polymyositis, inclusion body myositis, Chediak-Higashi syndrome, chronic granulomatous disease, Vitamin A deficiency, cancer (solid tumor,
- probiotic composition comprising UF1 and at least a second strain of probiotic bacteria and an acceptable carrier thereof.
- the second strain of probiotic bacteria is selected from: Propionibacterium acnes; Propionibacterium avidum; Propionibacterium granulosum; Propionibacterium lymphophilum; Propionibacterium acidiproprionic; Propionibacterium jensenii Propionibacterium thoenii ; and/or mixtures of the foregoing.
- “Acceptable carrier,” as used herein, includes any carrier which does not interfere with the effectiveness of the biological activity of the active ingredients and/or that is not toxic to the subject receiving such ingredients.
- Non-limiting examples of acceptable carriers include phosphate buffered saline solutions, water, emulsions, such as oil/water emulsions, various types of wetting agents and sterile solutions. Additional non-limiting examples of compatible carriers can include any suitable vehicle, delivery or dispensing means or material. Such acceptable carriers can be formulated by conventional methods and can be administered to the subject at an effective amount.
- the disclosed probiotic bacteria according to the invention may be produced using any standard fermentation process known in the art.
- solid substrate or submerged liquid fermentation can be mixed cultures, or single isolates.
- the probiotic bacteria are anaerobically fermented.
- the probiotic bacteria are a combination of solid substrate and a submerged liquid fermentation.
- compositions are formulated for oral administration including chewable foods, beverages, liquids, tablets, capsules, powders, and granulates.
- the compositions have been formulated into a tablet.
- the compositions have been formulated into a capsule.
- the compositions have been formulated into granulated or water soluble powders.
- compositions can be formulated into liquids, creams, lotions, gels dispersions or ointments for topical administration.
- the composition may contain further ingredients, including ingredients that have a favorable impact on health, flavor, formulating or tableting.
- additional ingredients that may suitably be incorporated in the present composition are: vitamins, minerals, nutritional supplements (e.g., fiber), fungal extracts, botanical extracts, sweeteners, flow aids, and fillers.
- Tableting aids include for example, carboxylic acids such as malic, maleic, citric, iso-citric and succinic, and salts thereof, SiO 2 , Aloe Vera, saturated and unsaturated linear and branched fatty acids and their salts, or fatty alcohols.
- Preferred tableting aides are malic acid, citric acid, stearic acid or Magnesium stearate. Tableting aides are formulated at a concentration of about 1% to 10%, w/w, 2.5% and 7.5 w/w % or any specific value within said range.
- a method of increasing the level of NAD+ and/or NMN levels in a subject comprising administering to the subject a composition comprising at least one strain of bacteria wherein the at least one strain of bacteria comprises Propionibacterium freudenreichii UF (UF1).
- a method of slowing aging in a subject comprising administering to the subject one or more sirtuin enhancer to the subject, wherein the one or more sirtuin enhancer comprises at least one strain of bacteria wherein the at least one strain of bacteria comprises Propionibacterium freudenreichii UF (UF1).
- administration of the sirtuin enhancer to the subject potentiates DNA repair of the subject.
- compositions of the disclosure may take the form of dietary supplements or may themselves be used in combination with dietary supplements, also referred to herein as food supplements.
- Nutritional supplements may be found in many forms such as tablets, capsules, soft gels, gel caps, liquids, or powders. Some dietary supplements can help ensure an adequate dietary intake of essential nutrients; others may help reduce risk of disease.
- compositions of the disclosure may take the form of a food product.
- the term “food” is used in a broad sense and covers food and drink for humans as well as food and drink for animals (i.e. a feed).
- the food product is suitable for, and designed for, human consumption.
- the food may be in the form of a liquid, solid or suspension, depending on the use and/or the mode of application and/or the mode of administration.
- the composition may comprise or be used in conjunction with one or more of: a nutritionally acceptable carrier, a nutritionally acceptable diluent, a nutritionally acceptable excipient, a nutritionally acceptable adjuvant, a nutritionally active ingredient.
- compositions of the disclosure may take the form of one of the following: A fruit juice; a beverage comprising whey protein: a health or herbal tea, a cocoa drink, a coffee drink, a yoghurt and/or a drinking yoghurt, a cheese, an ice cream, a desserts, a confectionery, a biscuit, a cake, cake mix or cake filling, a snack food, a fruit filling, a cake or doughnut icing, an instant bakery filling cream, a filling for cookies, a ready-to-use bakery filling, a reduced calorie filling, an adult nutritional beverage, an acidified soy/juice beverage, a nutritional or health bar, a beverage powder, a calcium fortified soy milk, or a calcium fortified coffee beverage.
- whey protein a health or herbal tea, a cocoa drink, a coffee drink, a yoghurt and/or a drinking yoghurt, a cheese, an ice cream, a desserts,
- compositions of the present disclosure may take the form of a food ingredient and/or feed ingredient.
- food ingredient or “feed ingredient” includes a composition which is or can be added to functional foods or foodstuffs as a nutritional and/or health supplement for humans and animals.
- the food ingredient may be in the form of a liquid, suspension or solid, depending on the use and/or the mode of application and/or the mode of administration.
- compositions of the disclosure may take the form of functional foods.
- the term “functional food” means food which is capable of providing not only a nutritional effect, but is also capable of delivering a further beneficial effect to the consumer.
- a probiotic composition comprising Propionibacterium freudenreichii UF (UF1). 2. The composition of clause 1, further comprising at least a second strain of probiotic bacteria. 3. The probiotic composition of clause 2, wherein the second strain of probiotic bacteria is selected from: Propionibacterium acnes; Propionibacterium avidum; Propionibacterium granulosum; Propionibacterium lymphophilum; Propionibacterium acidiproprionic; Propionibacterium jensenii Propionibacterium thoenii ; lactic acid bacteria including lactobacilli (sp. acidophilus, fermentum, plantarum, rhamnosus, casei, reuteri, gasseri ) and streptococci (e.g.
- probiotic composition any of clauses 1-3, further comprising a probiotic stabilizer.
- probiotic stabilizer is maltodextrin.
- a method for increasing vitamin B12 levels in a subject comprising administering to the subject a composition the probiotic composition of any of clauses 1-10. 7. The method of clause 1, wherein the UF1 is probiotic. 8.
- the composition administered delivers a dose of UF1 to the subject from about 5 ⁇ 10 8 to about 1 ⁇ 10 11 colony forming units (CFU).
- CFU colony forming units
- the dose of UF1 is from about 1 ⁇ 10 9 to about 2 ⁇ 10 10 CFU.
- the dose of UF1 is from about 5 ⁇ 10 9 to about 1 ⁇ 10 10 CFU.
- the composition administered delivers a dose of UF1 to the subject from about 5 ⁇ 10 8 to about 1 ⁇ 10 11 Active Fluorescent Units (AFU).
- AFU Active Fluorescent Units
- the administration of the composition confers at least on benefit on the subject selected from; an increase in serum levels of at least one of vitamin B2, B5, B6, B9, and/or B12; an increase in at least one of tryptophan, tyrosine, phenylalanine; increased propionic acid, immune system modulation and/or augmentation, regulation of TH17 cells; and/or reduction in pro-inflammatory metabolites.
- the at least one strain of bacteria comprises at least a second strain of bacteria.
- the second strain of bacteria is chosen from: Propionibacterium acnes; Propionibacterium avidum; Propionibacterium granulosum; Propionibacterium lymphophilum; Propionibacterium acidiproprionic; Propionibacterium jensenii Propionibacterium thoenii ; lactic acid bacteria including lactobacilli (ssp. acidophilus, fermentum, plantarum, rhamnosus, casei, reuteri, gasseri ) and streptococci (e.g. salivarius, thermophilus ), spore forming bacteria including Bacillus (e.g.
- a method for increasing vitamin B12 levels in a subject comprising administering to the subject a composition comprising: at least one species of bacteria wherein the at least species of bacteria comprises the species Propionibacterium freudenreichii (PF) 27.
- PF Propionibacterium freudenreichii
- the method of clause 26, wherein the composition administered delivers a dose of PF to the subject from about 5 ⁇ 10 8 to about 1 ⁇ 10 11 CFU. 28.
- the method of clause 27, wherein the dose of PF is from about 1 ⁇ 10 9 to about 2 ⁇ 10 10 CFU. 29.
- the method of clause 28, wherein the dose of PF is from about 5 ⁇ 10 9 to about 1 ⁇ 10 11 CFU.
- the composition administered delivers a dose of PF to the subject from about 5 ⁇ 10 8 to about 1 ⁇ 10 11 AFU. 31.
- the dose of PF is from about 1 ⁇ 10 9 to about 2 ⁇ 10 10 AFU.
- the dose of PF is from about 5 ⁇ 10 9 to about 1 ⁇ 10 10 .
- the composition further comprises a probiotic stabilizer (e.g. maltodextrin).
- a probiotic stabilizer e.g. maltodextrin.
- a method of slowing aging in a subject comprising administering to the subject one or more sirtuin enhancer to the subject, wherein the one or more sirtuin enhancer comprises at least one strain of bacteria wherein the at least one strain of bacteria comprises Propionibacterium freudenheimii UF (UF1). 36. The method of clause 35, wherein administration of the sirtuin enhancer to the subject potentiates DNA repair of the subject.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Disclosed herein is method for increasing vitamin B12 levels in a subject comprising administering to the subject a composition comprising: at least one strain of bacteria wherein the at least one strain of bacteria comprises Propionibacterium freudenreichii UF (UF1). In certain embodiments, the UF1 is probiotic. In certain implementations, the administration of the composition increases the subject's serum B12 levels by at least about 10% relative to the subject's serum B12 level prior to administration of the composition. In further embodiments, the administration of the composition confers at least on benefit on the subject selected from; an increase in serum levels of at least one of vitamin B2, B5, B6, B9, and/or B12; an increase in at least one of tryptophan, tyrosine, phenylalanine; increased propionic acid, immune system modulation and/or augmentation, regulation of TH17 cells; and/or reduction in pro-inflammatory metabolites.
Description
- This application claims priority to U.S. Provisional Application No. 63/180,520 filed Apr. 27, 2021, and entitled “PROBIOTIC COMPOSITIONS AND METHODS OF USE THEREOF,” which is hereby incorporated by reference in its entirety under 35 U.S.C. § 119(e).
- Vitamin B12 is important for the normal functioning of the brain and nervous system and for the formation of blood. It is involved in the metabolism of every cell of the body, especially affecting the DNA synthesis and regulation but also fatty acid synthesis and energy production. Its effects are still not completely known.
- Vitamin B12 deficiencies can result in significant damage to multiple organ systems and supplementation is often required, especially among individuals that have vegetarian or vegan diets, or that are pregnant. There is a need in the art for improved compositions and methods for supplementing vitamin B12.
- Disclosed herein is method for increasing vitamin B12 levels in a subject comprising administering to the subject a composition comprising: at least one strain of bacteria wherein the at least one strain of bacteria comprises Propionibacterium freudenreichii UF (UF1). In certain embodiments, the UF1 is probiotic. In further embodiments, the composition administered delivers a dose of UF1 to the subject from about 5×108 to about 1×1011 colony forming units (CFU). In yet further embodiments, the dose of UF1 is from about 1×109 to about 2×1010 CFU. in still further embodiments, the dose of UF1 is from about 5×109 to about 1×1010 CFU. According to certain embodiments, the composition administered delivers a dose of UF1 to the subject from about 5×108 to about 1×1011 Active Fluorescent Units (AFU). In further embodiments, the dose of UF1 is from about 1×109 to about 2×1010 AFU. In yet further embodiment, the dose of UF1 is from about 5×109 to about 1×1010 AFU.
- In certain embodiments, the UF1 is a mixture of probiotic and paraprobiotic. In exemplary implementations, the UF1 is parabiotic. In further embodiments, the UF1 is a probiotic, parabiotic, prebiotic, synbiotic, or mixture of the foregoing.
- In certain implementations, the administration of the composition increases the subject's serum B12 levels by at least about 10% relative to the subject's serum B12 level prior to administration of the composition. In further embodiments, the administration of the composition confers at least on benefit on the subject selected from; an increase in serum levels of at least one of vitamin B2, B5, B6, B9, and/or B12; an increase in at least one of tryptophan, tyrosine, phenylalanine; increased propionic acid, immune system modulation and/or augmentation, regulation of TH17 cells; and/or reduction in pro-inflammatory metabolites. In further embodiments, administration of the composition to the subject increases the level of NAD+ and or NMN levels in the subject.
- According to certain implementations, the at least one strain of bacteria comprises at least a second strain of bacteria chosen from: Propionibacterium acnes; Propionibacterium avidum; Propionibacterium granulosum; Propionibacterium lymphophilum; Propionibacterium acidiproprionic; Propionibacterium jensenii Propionibacterium thoenii; lactic acid bacteria including lactobacilli (ssp. acidophilus, fermentum, plantarum, rhamnosus, casei, reuteri, gasseri) and streptococci (e.g. salivarius, thermophilus), spore forming bacteria including Bacillus (e.g. coagulans, subtilis), bifidobacteria, yeast-derived bacteria including Saccharomyces boulardii, and/or mixtures of the foregoing.
- According to certain embodiments, the subject is an infant. In exemplary implementations of these embodiments, administration of the composition to the infant accelerates T-cell immunity, decreases neonatal adaptive immunity period, and/or increases pathogen resistance. In certain implementations, the infant was born preterm.
- Further disclosed herein is a method of slowing aging in a subject, comprising administering to the subject one or more sirtuin enhancer to the subject, wherein the one or more sirtuin enhancer comprises at least one strain of bacteria wherein the at least one strain of bacteria comprises Propionibacterium freudenreichii UF (UF1).
- Further disclosed herein is a probiotic composition comprising Propionibacterium freudenreichii UF (UF1) and at least a second strain of probiotic bacteria wherein the second strain of probiotic bacteria is selected from: Propionibacterium acnes; Propionibacterium avidum; Propionibacterium granulosum; Propionibacterium lymphophilum; Propionibacterium acidiproprionic; Propionibacterium jensenii Propionibacterium thoenii; lactic acid bacteria including lactobacilli (ssp. acidophilus, fermentum, plantarum, rhamnosus, casei, reuteri, gasseri) and streptococci (e.g. salivarius, thermophilus), spore forming bacteria including Bacillus (e.g. coagulans, subtilis), bifidobacteria, yeast-derived bacteria including Saccharomyces boulardii, prebiotics, and synbiotics and/or mixtures of the foregoing.
- Ranges can be expressed herein as from “about” one particular value, and/or to “about” another particular value. When such a range is expressed, a further aspect includes from the one particular value and/or to the other particular value. Similarly, when values are expressed as approximations, by use of the antecedent “about,” it will be understood that the particular value forms a further aspect. It will be further understood that the endpoints of each of the ranges are significant both in relation to the other endpoint, and independently of the other endpoint. It is also understood that there are a number of values disclosed herein, and that each value is also herein disclosed as “about” that particular value in addition to the value itself. For example, if the value “10” is disclosed, then “about 10” is also disclosed. It is also understood that each unit between two particular units are also disclosed. For example, if 10 and 15 are disclosed, then 11, 12, 13, and 14 are also disclosed.
- Certain materials, compounds, compositions, and components disclosed herein can be obtained commercially or readily synthesized using techniques generally known to those of skill in the art. For example, the starting materials and reagents used in preparing the disclosed compounds and compositions are either available from commercial suppliers such as Aldrich Chemical Co., (Milwaukee, Wis.), Acros Organics (Morris Plains, N.J.), Fisher Scientific (Pittsburgh, Pa.), or Sigma (St. Louis, Mo.) or are prepared by methods known to those skilled in the art following procedures set forth in references such as Fieser and Fieser's Reagents for Organic Synthesis, Volumes 1-17 (John Wiley and Sons, 1991); Rodd's Chemistry of Carbon Compounds, Volumes 1-5 and Supplementals (Elsevier Science Publishers, 1989); Organic Reactions, Volumes 1-40 (John Wiley and Sons, 1991); March's Advanced Organic Chemistry, (John Wiley and Sons, 4th Edition); and Larock's Comprehensive Organic Transformations (VCH Publishers Inc., 1989).
- As used herein, “probiotic bacteria” or “probiotics” as used herein, refers to microorganisms which when administered for nutritional supplementation in adequate amounts confer a health benefit to the subject. Heath benefit can be measured by any method known in the art, for example, as indicated by biochemical markers including for example, blood sugar levels, lipid chemistry, liver function, full blood count, thyroid function, markers of inflammation (ESR and C-reactive protein), and stool classifications.
- A probiotic, such as the composition disclosed herein, is optionally combined with at least one suitable prebiotic compound. A prebiotic compound is usually a non-digestible carbohydrate such as an oligo- or polysaccharide, or a sugar alcohol, which is not degraded or absorbed in the upper digestive tract. Known prebiotics include commercial products such as inulin and transgalacto-oligosaccharides.
- As used herein, “paraprobiotic bacteria” or “paraprobiotic” means those products comprising killed or inactivated microbes which may positively affect subject health.
- As used herein, the term “probiotic composition” can refer to a composition containing at least one species, genus, family, strain, order, or class of probiotic bacteria (e.g., a single isolate or a combination of desired bacteria), and can also include any additional carriers, excipients, and/or therapeutic agents that can be administered to a mammal. In certain embodiments, the probiotic composition comprises a buffering agent to allow the probiotic bacteria to survive in the acidic environment of the stomach, that is, the probiotic bacteria resist low pH and are able to survive passage through the stomach to colonize and grow in the intestinal milieu. Buffering agents can include, for example, sodium bicarbonate, milk, yoghurt, infant formula, and other dairy products. In certain embodiments, the probiotic composition is formulated as a food additive. In certain embodiments, the probiotic composition includes other materials known in the art for inclusion in food additives, such as water or other aqueous solutions, starch, binders, thickeners, colorants, flavorants, odorants, acidulants (e.g., lactic acid or malic acid, among others), vitamins, or minerals, among others.
- As used herein, the term “treatment” refers to the medical management of a patient with the intent to cure, ameliorate, stabilize, or prevent a disease, pathological condition, or disorder. This term includes active treatment, that is, treatment directed specifically toward the improvement of a disease, pathological condition, or disorder, and also includes causal treatment, that is, treatment directed toward removal of the cause of the associated disease, pathological condition, or disorder. In addition, this term includes palliative treatment, that is, treatment designed for the relief of symptoms rather than the curing of the disease, pathological condition, or disorder; preventative treatment, that is, treatment directed to minimizing or partially or completely inhibiting the development of the associated disease, pathological condition, or disorder; and supportive treatment, that is, treatment employed to supplement another specific therapy directed toward the improvement of the associated disease, pathological condition, or disorder. In various aspects, the term covers any treatment of a subject, including a mammal (e.g., a human), and includes: (i) preventing the disease from occurring in a subject that can be predisposed to the disease but has not yet been diagnosed as having it; (ii) inhibiting the disease, i.e., arresting its development; or (iii) relieving the disease, i.e., causing regression of the disease. In one aspect, the subject is a mammal such as a primate, and, in a further aspect, the subject is a human. The term “subject” also includes domesticated animals (e.g., cats, dogs, etc.), livestock (e.g., cattle, horses, pigs, sheep, goats, etc.), and laboratory animals (e.g., mouse, rabbit, rat, guinea pig, fruit fly, etc.).
- As used herein, the terms “effective amount” and “amount effective” refer to an amount that is sufficient to achieve the desired result or to have an effect on an undesired condition. For example, a “therapeutically effective amount” refers to an amount that is sufficient to achieve the desired therapeutic result or to have an effect on undesired symptoms, but is generally insufficient to cause adverse side effects. The specific therapeutically effective dose level for any particular patient will depend upon a variety of factors including the disorder being treated and the severity of the disorder; the specific composition employed; the age, body weight, general health, sex and diet of the patient; the time of administration; the route of administration; the rate of excretion of the specific compound employed; the duration of the treatment; drugs used in combination or coincidental with the specific compound employed and like factors well known in the medical arts. For example, it is well within the skill of the art to start doses of a compound at levels lower than those required to achieve the desired therapeutic effect and to gradually increase the dosage until the desired effect is achieved. If desired, the effective daily dose can be divided into multiple doses for purposes of administration. Consequently, single dose compositions can contain such amounts or submultiples thereof to make up the daily dose. The dosage can be adjusted by the individual physician in the event of any contraindications. Dosage can vary, and can be administered in one or more dose administrations daily, for one or several days. Guidance can be found in the literature for appropriate dosages for given classes of pharmaceutical products. In further various aspects, a preparation can be administered in a “prophylactically effective amount”; that is, an amount effective for prevention of a disease or condition.
- As used herein, the term “substantially” refers to the complete or nearly complete extent or degree of an action, characteristic, property, state, structure, item, or result. For example, an object that is “substantially” enclosed would mean that the object is either completely enclosed or nearly completely enclosed. The exact allowable degree of deviation from absolute completeness may in some cases depend on the specific context. However, generally speaking the nearness of completion will be so as to have the same overall result as if absolute and total completion were obtained. The use of “substantially” is equally applicable when used in a negative connotation to refer to the complete or near complete lack of an action, characteristic, property, state, structure, item, or result. For example, a composition that is “substantially free of” particles would either completely lack particles, or so nearly completely lack particles that the effect would be the same as if it completely lacked particles. In other words, a composition that is “substantially free of an ingredient or element may still actually contain such item as long as there is no measurable effect thereof.
- Propionibacterium freudenreichii is a gram-positive, non-motile bacterium that plays an important role in the creation of Emmental cheese, and to some extent, Jarlsberg cheese, Leerdammer and Maasdam cheese. Its concentration in Swiss-type cheeses is higher than in any other cheese. Propionibacterium strain, P. UF1, has been isolated from the gut microbiota of preterm infants. P. UF1 is also referred to herein as Propionibacterium freudenreichii UF1 or UF1. Disclosed herein is a method for increasing vitamin B12 levels in a subject comprising administering to the subject a composition comprising: at least one strain of bacteria wherein the at least one strain of bacteria comprises Propionibacterium freudenreichii UF (UF1). In certain embodiments, the composition administered delivers a dose of UF1 to the subject from about 5×108 to about 1×1011 colony forming units (CFU). In further embodiments, the dose of UF1 provided is from about 1×109 to about 2×1010 CFU. In still further embodiments, the dose of UF1 is from about 5×109 to about 1×1010 CFU.
- In certain further embodiments, the amount of UF1 present in a dose is determined by flow cytometry to determine the number of live cells, as measured by Active Fluorescent Units (AFU). In certain aspects, the composition administered delivers a dose of UF1 to the subject from about 5×108 to about 1×1011 AFU. In further embodiments, the dose of UF1 provided is from about 1×109 to about 2×1010 AFU. In still further embodiments, the dose of UF1 is from about 5×109 to about 1×1010 AFU.
- In certain embodiments, the at least one strain of bacteria is a probiotic. In further embodiments, the at least once strain of bacteria is a paraprobiotic.
- In yet further embodiments, the composition further comprises a prebiotic and/or a synbiotic. In even further embodiments, the at least on strain of bacteria is a mixture of a probiotic and paraprobiotic, prebiotic, and/or synbiotic.
- According to certain aspects, administration of the disclosed composition increases the subject's serum B12 levels. This is surprising given that it has been viewed as unlikely that administration of a probiotic vB12 producing bacteria would be able to affect serum vB12 levels. This is because while Propionibacterium UF1 is known to produce vB12 under industrial or lab conditions, it is unlikely that a substrate required by make B12 by UF1 occurs in the human gut. Furthermore, B12 is absorbed in the small intestine. B12 must be combined with intrinsic factor, a protein that is produced in the stomach to be absorbed. Probiotics usually reside (they are transient and do not colonize) in the large intestine, meaning the probiotic would be making B12 in the large intestine which is past its site of absorption.
- In certain embodiments, administration of the disclosed composition to a subject results in an increases in serum B12 level in the subject by at least 5%, at least 10%, at least 25%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or more, compared to the subject's B12 serum level prior to administration of the composition.
- In certain aspects, administration of the disclosed composition confers at least or many benefits on the subject. In certain aspects, the subject has reduced inflammation. In another embodiments, the subject has an increase in serum levels of at least one of vitamin B2, B5, B6, B9, and/or B12. In a further embodiment, the subject has an increase in levels of at least one amino acid. These include, but are not limited to tryptophan, tyrosine, and/or phenylalanine. In a further embodiment, the subject has increased levels of propionic acid, which in turn can has a positive impact on the intestinal regulatory cells, including induced T regulatory cells (Treg cells).
- In further embodiments, the subject has benefits to immune system modulation and/or augmentation. In yet further embodiments, the subject has beneficial effects on the regulation of TH17 cells. In still further embodiments, the subject has a reduction in pro-inflammatory metabolites.
- According to certain embodiments, the probiotic composition also includes one or more additional strain of bacteria. In certain implementations, this may include one or more of: Propionibacterium acnes; Propionibacterium avidum; Propionibacterium granulosum; Propionibacterium lymphophilum; Propionibacterium acidiproprionic; Propionibacterium jensenii Propionibacterium thoenii; lactic acid bacteria including lactobacilli (ssp. acidophilus, fermentum, plantarum, rhamnosus, casei, reuteri, gasseri) and streptococci (e.g. salivarius, thermophilus), spore forming bacteria including Bacillus (e.g. coagulans, subtilis), bifidobacteria, yeast-derived bacteria including Saccharomyces boulardii, and/or mixtures of the foregoing. In certain further embodiments, second strain of bacteria is a probiotic or a parabiotic or a mixture of the foregoing. In further embodiments, the composition further comprises a prebiotic, and/or synbiotic or mixtures of the foregoing.
- According to certain further embodiments, the subject is an infant. In exemplary implementations, the infant experiences one or more of the following benefits from administration of the probiotic composition: accelerated T-cell immunity, decreased neonatal adaptive immunity period, and/or increased pathogen resistance. In certain exemplary implementations, the infant was born preterm.
- Further disclosed herein is reducing inflammation in a subject in need thereof, comprising administering to the subject a composition disclosed herein. In certain embodiments the subject has an inflammatory disease or condition. An inflammatory disease or condition may include, but is not limited to: acne vulgaris, asthma, COPD, autoimmune diseases, celiac disease, chronic (plaque) prostatitis, glomerulonephritis, hypersensitivities, inflammatory bowel diseases (IBD, Crohn's disease, ulcerative colitis), pelvic inflammatory disease, reperfusion injury, rheumatoid arthritis, sarcoidosis, transplant rejection, vasculitis, interstitial cystitis, atherosclerosis, allergies (type 1, 2, and 3 hypersensitivity, hay fever), inflammatory myopathies, as systemic sclerosis, and include dermatomyositis, polymyositis, inclusion body myositis, Chediak-Higashi syndrome, chronic granulomatous disease, Vitamin A deficiency, cancer (solid tumor, gallbladder carcinoma), periodontitis, granulomatous inflammation (tuberculosis, leprosy, sarcoidosis, and syphilis), fibrinous inflammation, purulent inflammation, serous inflammation, ulcerative inflammation, and ischemic heart disease, type I diabetes, and diabetic nephropathy. In certain exemplary implementations, the inflammatory disease or condition is Necrotizing enterocolitis. In further exemplary implementations, administration of the probiotic composition reduces prostaglandin E1 and/or 20-hydroxyleukotriene E4 in the subject.
- Further disclosed herein is probiotic composition comprising UF1 and at least a second strain of probiotic bacteria and an acceptable carrier thereof. In certain embodiments, the second strain of probiotic bacteria is selected from: Propionibacterium acnes; Propionibacterium avidum; Propionibacterium granulosum; Propionibacterium lymphophilum; Propionibacterium acidiproprionic; Propionibacterium jensenii Propionibacterium thoenii; and/or mixtures of the foregoing. “Acceptable carrier,” as used herein, includes any carrier which does not interfere with the effectiveness of the biological activity of the active ingredients and/or that is not toxic to the subject receiving such ingredients. Non-limiting examples of acceptable carriers include phosphate buffered saline solutions, water, emulsions, such as oil/water emulsions, various types of wetting agents and sterile solutions. Additional non-limiting examples of compatible carriers can include any suitable vehicle, delivery or dispensing means or material. Such acceptable carriers can be formulated by conventional methods and can be administered to the subject at an effective amount.
- The disclosed probiotic bacteria according to the invention may be produced using any standard fermentation process known in the art. For example, solid substrate or submerged liquid fermentation. The fermented cultures can be mixed cultures, or single isolates. The probiotic bacteria are anaerobically fermented. The probiotic bacteria are a combination of solid substrate and a submerged liquid fermentation.
- The disclosed compositions are formulated for oral administration including chewable foods, beverages, liquids, tablets, capsules, powders, and granulates. In a preferred embodiment the compositions have been formulated into a tablet. In another preferred embodiment the compositions have been formulated into a capsule. In yet another preferred embodiment the compositions have been formulated into granulated or water soluble powders. Further, in certain embodiments, compositions can be formulated into liquids, creams, lotions, gels dispersions or ointments for topical administration.
- When formulated the composition may contain further ingredients, including ingredients that have a favorable impact on health, flavor, formulating or tableting. Non-limiting examples of additional ingredients that may suitably be incorporated in the present composition are: vitamins, minerals, nutritional supplements (e.g., fiber), fungal extracts, botanical extracts, sweeteners, flow aids, and fillers.
- Tableting aids include for example, carboxylic acids such as malic, maleic, citric, iso-citric and succinic, and salts thereof, SiO2, Aloe Vera, saturated and unsaturated linear and branched fatty acids and their salts, or fatty alcohols. Preferred tableting aides are malic acid, citric acid, stearic acid or Magnesium stearate. Tableting aides are formulated at a concentration of about 1% to 10%, w/w, 2.5% and 7.5 w/w % or any specific value within said range.
- Further disclosed herein is a method of increasing the level of NAD+ and/or NMN levels in a subject comprising administering to the subject a composition comprising at least one strain of bacteria wherein the at least one strain of bacteria comprises Propionibacterium freudenreichii UF (UF1).
- Further disclosed herein is a method of slowing aging in a subject, comprising administering to the subject one or more sirtuin enhancer to the subject, wherein the one or more sirtuin enhancer comprises at least one strain of bacteria wherein the at least one strain of bacteria comprises Propionibacterium freudenreichii UF (UF1). In certain embodiments, administration of the sirtuin enhancer to the subject potentiates DNA repair of the subject.
- The compositions of the disclosure may take the form of dietary supplements or may themselves be used in combination with dietary supplements, also referred to herein as food supplements.
- Nutritional supplements may be found in many forms such as tablets, capsules, soft gels, gel caps, liquids, or powders. Some dietary supplements can help ensure an adequate dietary intake of essential nutrients; others may help reduce risk of disease.
- The compositions of the disclosure may take the form of a food product. Here, the term “food” is used in a broad sense and covers food and drink for humans as well as food and drink for animals (i.e. a feed). Preferably, the food product is suitable for, and designed for, human consumption.
- The food may be in the form of a liquid, solid or suspension, depending on the use and/or the mode of application and/or the mode of administration.
- When in the form of a food product, the composition may comprise or be used in conjunction with one or more of: a nutritionally acceptable carrier, a nutritionally acceptable diluent, a nutritionally acceptable excipient, a nutritionally acceptable adjuvant, a nutritionally active ingredient.
- By way of example, the compositions of the disclosure may take the form of one of the following: A fruit juice; a beverage comprising whey protein: a health or herbal tea, a cocoa drink, a coffee drink, a yoghurt and/or a drinking yoghurt, a cheese, an ice cream, a desserts, a confectionery, a biscuit, a cake, cake mix or cake filling, a snack food, a fruit filling, a cake or doughnut icing, an instant bakery filling cream, a filling for cookies, a ready-to-use bakery filling, a reduced calorie filling, an adult nutritional beverage, an acidified soy/juice beverage, a nutritional or health bar, a beverage powder, a calcium fortified soy milk, or a calcium fortified coffee beverage.
- Compositions of the present disclosure may take the form of a food ingredient and/or feed ingredient. As used herein the term “food ingredient” or “feed ingredient” includes a composition which is or can be added to functional foods or foodstuffs as a nutritional and/or health supplement for humans and animals.
- The food ingredient may be in the form of a liquid, suspension or solid, depending on the use and/or the mode of application and/or the mode of administration.
- Compositions of the disclosure may take the form of functional foods.
- As used herein, the term “functional food” means food which is capable of providing not only a nutritional effect, but is also capable of delivering a further beneficial effect to the consumer.
- Various aspects and embodiments of the present invention are defined by the following numbered clauses:
- 1. A probiotic composition comprising Propionibacterium freudenreichii UF (UF1).
2. The composition of clause 1, further comprising at least a second strain of probiotic bacteria.
3. The probiotic composition of clause 2, wherein the second strain of probiotic bacteria is selected from: Propionibacterium acnes; Propionibacterium avidum; Propionibacterium granulosum; Propionibacterium lymphophilum; Propionibacterium acidiproprionic; Propionibacterium jensenii Propionibacterium thoenii; lactic acid bacteria including lactobacilli (ssp. acidophilus, fermentum, plantarum, rhamnosus, casei, reuteri, gasseri) and streptococci (e.g. salivarius, thermophilus), spore forming bacteria including Bacillus (e.g. coagulans, subtilis), bifidobacteria, yeast-derived bacteria including Saccharomyces boulardii, prebiotics, and synbiotics and/or mixtures of the foregoing.
4. The probiotic composition any of clauses 1-3, further comprising a probiotic stabilizer.
5. The probiotic composition of clause 4, wherein the probiotic stabilizer is maltodextrin.
6. A method for increasing vitamin B12 levels in a subject comprising administering to the subject a composition the probiotic composition of any of clauses 1-10.
7. The method of clause 1, wherein the UF1 is probiotic.
8. The method of clause 7, wherein the composition administered delivers a dose of UF1 to the subject from about 5×108 to about 1×1011 colony forming units (CFU).
9. The method of clause 8, wherein the dose of UF1 is from about 1×109 to about 2×1010 CFU.]
10. The method of clause 9, wherein the dose of UF1 is from about 5×109 to about 1×1010 CFU.
11. The method of clause 6, wherein the composition administered delivers a dose of UF1 to the subject from about 5×108 to about 1×1011 Active Fluorescent Units (AFU).
12. The method of clause 11, wherein the dose of UF1 is from about 1×109 to about 2×1010 AFU.
13. The method of clause 12, wherein the dose of UF1 is from about 5×109 to about 1×1010 AFU.
14. The method of clause 6, wherein the UF1 is a mixture of probiotic and paraprobiotic.
15. The method of clause 6, wherein the UF1 is parabiotic.
16. The method of clause 15, wherein the parabiotic UF1 is inactivated through heat treatment, or chemicals, or gamma rays, or ultraviolet rays, or sonication.
17. The method of clause 6, wherein the UF1 is a probiotic, parabiotic, prebiotic, synbiotic, or mixture of the foregoing.
18. The method of any preceding clause, wherein the administration of the composition increases the subject's serum B12 levels.
19. The method of any preceding clause, wherein the administration of the composition confers at least on benefit on the subject selected from; an increase in serum levels of at least one of vitamin B2, B5, B6, B9, and/or B12; an increase in at least one of tryptophan, tyrosine, phenylalanine; increased propionic acid, immune system modulation and/or augmentation, regulation of TH17 cells; and/or reduction in pro-inflammatory metabolites.
20. The method of any preceding clause, wherein the at least one strain of bacteria comprises at least a second strain of bacteria.
21. The method of clause 20, wherein the second strain of bacteria is chosen from: Propionibacterium acnes; Propionibacterium avidum; Propionibacterium granulosum; Propionibacterium lymphophilum; Propionibacterium acidiproprionic; Propionibacterium jensenii Propionibacterium thoenii; lactic acid bacteria including lactobacilli (ssp. acidophilus, fermentum, plantarum, rhamnosus, casei, reuteri, gasseri) and streptococci (e.g. salivarius, thermophilus), spore forming bacteria including Bacillus (e.g. coagulans, subtilis), bifidobacteria, yeast-derived bacteria including Saccharomyces boulardii, and/or mixtures of the foregoing.
22. The method of clause 21 wherein the second strain of bacteria is a probiotic, parabiotic, prebiotic, and/or synbiotic, and/or mixture of the foregoing.
23. The method of any preceding clause, wherein the subject is an infant.
24. The method of clause 23, wherein administration of the composition to the infant accelerates T-cell immunity, decreases neonatal adaptive immunity period, and/or increases pathogen resistance.
25. The method of clause 24, wherein the infant was born preterm.
26. A method for increasing vitamin B12 levels in a subject comprising administering to the subject a composition comprising: at least one species of bacteria wherein the at least species of bacteria comprises the species Propionibacterium freudenreichii (PF)
27. The method of clause 26, wherein the composition administered delivers a dose of PF to the subject from about 5×108 to about 1×1011 CFU.
28. The method of clause 27, wherein the dose of PF is from about 1×109 to about 2×1010 CFU.
29. The method of clause 28, wherein the dose of PF is from about 5×109 to about 1×1011 CFU.
30. The method of clause 26, wherein the composition administered delivers a dose of PF to the subject from about 5×108 to about 1×1011 AFU.
31. The method of clause 30, wherein the dose of PF is from about 1×109 to about 2×1010 AFU.
32. The method of clause 31, wherein the dose of PF is from about 5×109 to about 1×1010.
33. The method of clause any preceding clause, wherein the composition further comprises a probiotic stabilizer (e.g. maltodextrin).
34. A method of increasing the level of NAD+ and or NMN levels in a subject comprising administering to the subject a composition comprising: at least one strain of bacteria wherein the at least one strain of bacteria comprises Propionibacterium freudenreichii UF (UF1).
35. A method of slowing aging in a subject, comprising administering to the subject one or more sirtuin enhancer to the subject, wherein the one or more sirtuin enhancer comprises at least one strain of bacteria wherein the at least one strain of bacteria comprises Propionibacterium freudenreichii UF (UF1).
36. The method of clause 35, wherein administration of the sirtuin enhancer to the subject potentiates DNA repair of the subject. - While multiple embodiments are disclosed, still other embodiments of the disclosure will become apparent to those skilled in the art from the following detailed description, which shows and describes illustrative embodiments of the disclosed compositions, systems and methods. As will be realized, the disclosed compositions, systems and methods are capable of modifications in various obvious aspects, all without departing from the spirit and scope of the disclosure. Accordingly, the detailed description is to be regarded as illustrative in nature and not restrictive.
Claims (20)
1. A method for increasing vitamin B12 levels in a subject comprising administering to the subject a composition comprising: at least one strain of bacteria wherein the at least one strain of bacteria comprises Propionibacterium freudenreichii UF (UF1).
2. The method of claim 1 , wherein the UF1 is probiotic.
3. The method of claim 2 , wherein the composition administered delivers a dose of UF1 to the subject from about 5×108 to about 1×1011 colony forming units (CFU).
4. The method of claim 3 , wherein the dose of UF1 is from about 1×109 to about 2×1010 CFU.
5. The method of claim 4 , wherein the dose of UF1 is from about 5×109 to about 1×1010 CFU.
6. The method of claim 1 , wherein the composition administered delivers a dose of UF1 to the subject from about 5×108 to about 1×1011 Active Fluorescent Units (AFU).
7. The method of claim 6 , wherein the dose of UF1 is from about 1×109 to about 2×1010 AFU.
8. The method of claim 7 , wherein the dose of UF1 is from about 5×109 to about 1×1010 AFU.
9. The method of claim 1 , wherein the UF1 is a mixture of probiotic and paraprobiotic.
10. The method of claim 1 , wherein the UF1 is parabiotic.
11. The method of claim 1 , wherein the UF1 is a probiotic, parabiotic, prebiotic, synbiotic, or mixture of the foregoing.
12. The method of claim 1 , wherein the administration of the composition increases the subject's serum B12 levels by at least about 10% relative to the subject's serum B12 level prior to administration of the composition.
13. The method of claim 1 , wherein the administration of the composition confers at least on benefit on the subject selected from; an increase in serum levels of at least one of vitamin B2, B5, B6, B9, and/or B12; an increase in at least one of tryptophan, tyrosine, phenylalanine; increased propionic acid, immune system modulation and/or augmentation, regulation of TH17 cells; and/or reduction in pro-inflammatory metabolites.
14. The method of claim 1 , wherein administration of the composition to the subject increases the level of NAD+ and or NMN levels in the subject.
15. The method of claim 1 , wherein the at least one strain of bacteria comprises at least a second strain of bacteria chosen from: Propionibacterium acnes; Propionibacterium avidum; Propionibacterium granulosum; Propionibacterium lymphophilum; Propionibacterium acidiproprionic; Propionibacterium jensenii Propionibacterium thoenii; lactic acid bacteria including lactobacilli (ssp. acidophilus, fermentum, plantarum, rhamnosus, casei, reuteri, gasseri) and streptococci (e.g. salivarius, thermophilus), spore forming bacteria including Bacillus (e.g. coagulans, subtilis), bifidobacteria, yeast-derived bacteria including Saccharomyces boulardii, and/or mixtures of the foregoing.
16. The method of claim 1 , wherein the subject is an infant.
17. The method of claim 16 , wherein administration of the composition to the infant accelerates T-cell immunity, decreases neonatal adaptive immunity period, and/or increases pathogen resistance.
18. The method of claim 17 , wherein the infant was born preterm.
19. A method of slowing aging in a subject, comprising administering to the subject one or more sirtuin enhancer to the subject, wherein the one or more sirtuin enhancer comprises at least one strain of bacteria wherein the at least one strain of bacteria comprises Propionibacterium freudenreichii UF (UF1).
20. A probiotic composition comprising Propionibacterium freudenreichii UF (UF1) and at least a second strain of probiotic bacteria wherein the second strain of probiotic bacteria is selected from: Propionibacterium, acnes; Propionibacterium avidum; Propionibacterium granulosum; Propionibacterium lymphophilum; Propionibacterium acidiproprionic; Propionibacterium jensenii Propionibacterium thoenii; lactic acid bacteria including lactobacilli (ssp. acidophilus, fermentum, plantarum, rhamnosus, casei, reuteri, gasseri) and streptococci (e.g. salivarius, thermophilus), spore forming bacteria including Bacillus (e.g. coagulans, subtilis), bifidobacteria, yeast-derived bacteria including Saccharomyces boulardii, prebiotics, and synbiotics and/or mixtures of the foregoing.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/730,850 US20220339213A1 (en) | 2021-04-27 | 2022-04-27 | Probiotic compositions and methods of use thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202163180520P | 2021-04-27 | 2021-04-27 | |
US17/730,850 US20220339213A1 (en) | 2021-04-27 | 2022-04-27 | Probiotic compositions and methods of use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
US20220339213A1 true US20220339213A1 (en) | 2022-10-27 |
Family
ID=83694979
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/730,850 Pending US20220339213A1 (en) | 2021-04-27 | 2022-04-27 | Probiotic compositions and methods of use thereof |
Country Status (1)
Country | Link |
---|---|
US (1) | US20220339213A1 (en) |
-
2022
- 2022-04-27 US US17/730,850 patent/US20220339213A1/en active Pending
Non-Patent Citations (5)
Title |
---|
Bernardeau et al. (J Appl Microbiol, 2001, vol 91:1103-1109) (Year: 2001) * |
Brasili et al. (J Nutrition, 2013, v 143(10):1549-1557) (Year: 2013) * |
Nataraj et al. (Microb Cell Fact, 2020, v 19:168-189) (Year: 2020) * |
Torow et al. (J Immunol, 2017, vol 198(2):557-563) (Year: 2017) * |
Woodard et al. (J Gastrointest Surg, 2009, v 13:1198-1204) (Year: 2009) * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Singh et al. | Probiotics: A review | |
KR101618391B1 (en) | Lactic acid bacterium having high oxalic acid decomposition ability | |
JP7296454B2 (en) | Combinations of probiotics for the treatment of inflammation-related gastrointestinal disorders | |
US20210060096A1 (en) | Methods and compositions using bifidobacterium longum to modulate emotional reactivity and treat or prevent sub-clinical mood disturbances | |
US20160303226A1 (en) | Heat-treated formulation of bifidobacterium lactis ncc 2818 reduces allergic manifestations | |
JP5592640B2 (en) | Antistress agent containing lactic acid bacteria fermented royal jelly, method for producing the same, hypothalamus-pituitary-adrenocortical activity inhibitor, and sympathetic-adrenal medullary activity inhibitor | |
AU2018310705B2 (en) | Probiotic bacteria preconditioned in a GOS-containing medium and use thereof | |
CN111212575A (en) | Composition for muscle building | |
JP3784045B2 (en) | LDL oxidation-suppressing food and drink and pharmaceuticals | |
WO2024027401A1 (en) | Method and composition for improving intestinal microbiota | |
JP2005522216A (en) | Novel fungus producing conjugated linoleic acid, capsule containing the same and method for producing the same | |
CN111713555A (en) | Probiotic fermented camel milk capable of relaxing bowels and preparation method thereof | |
CN114761029A (en) | Compositions and methods having probiotics and N-3 fatty acids for preventing or treating mastitis | |
CN111201026B (en) | Fermented milk and polysaccharides with cancer cachexia inhibiting effect | |
EP3479836B1 (en) | Cartilage regeneration facilitating composition | |
JP2014166972A (en) | Intestinal inflammation inhibitor and food and drink | |
WO2002080947A1 (en) | Compositions containing bacterium capable of converting lactic acid into butyric acid and method of preventing/treating hyperlactic acidemia in digestive tract and colon cancer by using the same | |
US20220339213A1 (en) | Probiotic compositions and methods of use thereof | |
WO2024055983A1 (en) | Composition of pumpkin seed protein and use thereof | |
JP5940475B2 (en) | Blood cortisol elevation inhibitor | |
KR102606636B1 (en) | Bacillus velezensis having the effect of preventing or improving for sarcopenia and uses thereof | |
JP7430312B2 (en) | Composition for promoting intestinal short-chain fatty acid production and food and beverages containing the same | |
JP2018174772A (en) | Methods for producing lactic acid bacteria, and compositions for immunity modulation | |
Soleymanzadeh Moghadam et al. | Does Probiotic Therapy Have Effect on Serum Calcium and Cholesterol Levels in Demyelinated Hippocampus? | |
CN117731014A (en) | Sunflower seed protein composition and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |